US Bancorp DE Acquires 548 Shares of GeneDx Holdings Corp. $WGS

US Bancorp DE lifted its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 3,223.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 565 shares of the company’s stock after purchasing an additional 548 shares during the period. US Bancorp DE’s holdings in GeneDx were worth $50,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sterling Capital Management LLC increased its position in shares of GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after acquiring an additional 316 shares during the period. Lazard Asset Management LLC purchased a new position in shares of GeneDx in the fourth quarter valued at about $35,000. GAMMA Investing LLC increased its position in shares of GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock valued at $39,000 after acquiring an additional 264 shares during the period. Comerica Bank purchased a new position in shares of GeneDx in the fourth quarter valued at about $50,000. Finally, Quarry LP purchased a new position in shares of GeneDx in the fourth quarter valued at about $78,000. Institutional investors own 61.72% of the company’s stock.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 388 shares of the company’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $105.31, for a total transaction of $40,860.28. Following the completion of the transaction, the chief financial officer owned 3,757 shares in the company, valued at approximately $395,649.67. This represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Katherine Stueland sold 2,154 shares of the company’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $105.31, for a total transaction of $226,837.74. Following the transaction, the chief executive officer owned 3,440 shares of the company’s stock, valued at approximately $362,266.40. This represents a 38.51% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,411 shares of company stock valued at $2,085,051. 29.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on WGS shares. Piper Sandler set a $120.00 target price on shares of GeneDx and gave the company an “overweight” rating in a research note on Monday, August 4th. Guggenheim reaffirmed a “buy” rating and set a $115.00 target price (up previously from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Wells Fargo & Company lifted their target price on shares of GeneDx from $78.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Jefferies Financial Group raised shares of GeneDx from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Friday, May 9th. Finally, Wall Street Zen raised shares of GeneDx from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $101.63.

GeneDx Stock Down 4.2%

Shares of GeneDx stock opened at $120.65 on Wednesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. The stock has a market capitalization of $3.47 billion, a PE ratio of 2,413.00 and a beta of 2.02. GeneDx Holdings Corp. has a 52-week low of $28.86 and a 52-week high of $127.55. The company has a 50-day simple moving average of $90.48 and a two-hundred day simple moving average of $86.38.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The business had revenue of $102.69 million during the quarter, compared to analysts’ expectations of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.